Biologics in COPD by Ana L. Kersul, Borja G. Cosio

Get full text

Biologics in brain repair by Michel Modo, Kyle Fink, Julien Rossignol

Get full text

Nanomedicines for the Delivery of Biologics by John Wahlich, Arpan Desai, Francesca Greco, Kathryn Hill, Arwyn T. Jones, Randall J. Mrsny, Gianfranco Pasut, Yvonne Perrie, F. Philipp Seib, Leonard W. Seymour, Ijeoma F. Uchegbu

“…A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. …”
Get full text

Biologics for chronic rhinosinusitis by Chong, L-Y, Piromchai, P, Sharp, S, Snidvongs, K, Webster, KE, Philpott, C, Hopkins, C, Burton, MJ

“…It occurs with or without nasal polyps. </p> <p>'Biologics' are medicinal products produced by a biological process. …”

Blueprint for antibody biologics developability by Carl Mieczkowski, Xuejin Zhang, Dana Lee, Khanh Nguyen, Wei Lv, Yanling Wang, Yue Zhang, Jackie Way, Jean-Michel Gries

Subjects: Get full text

The other side of biologics for psoriasis by Chao-Chun Yang

Get full text

Pharmacokinetics of biologics in gastric cancer by Junyi Li, David C. Turner, Feifei Li, Xi Chen, Michael Z. Liao, Chunze Li

“…Abstract Gastric cancer (GC) remains one of the leading causes of cancer death worldwide despite improvements in therapeutic options. Several biologics have been investigated in patients with GC, including those approved in other solid tumors; however, the success rate of the pivotal trials that investigated these biologic molecules in GC remains low. …”
Get full text

FDA Approvals of Biologics in 2022 by Alexander C. Martins, Fernando Albericio, Beatriz G. de la Torre

Subjects: Get full text

Management of biologics in oral surgery by Mills Sophie, Ryan Patrick, Gaffney Karl

Subjects: “…biological products…”
Get full text

Evolution of Biologics Screening Technologies by Matthew J. Gardener, Peter Cariuk, Tristan J. Vaughan

“…Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. …”
Get full text

Emerging biologics in severe asthma by Pavord, I, Hilvering, B, Shrimanker, R

Biosimilars : design and analysis of follow-on biologics / by Chow, Shein-Chung, 1955- author

Subjects:

Tailored Biologics Selection in Severe Asthma by Sang Hyuk Kim, Youlim Kim

Subjects: Get full text

An update on the biologics for the treatment of antiphospholipid syndrome by Zelin Yun, Zelin Yun, Lizhi Duan, Xiangjun Liu, Xiangjun Liu, Qingmeng Cai, Qingmeng Cai, Chun Li, Chun Li

Subjects: “…biologics…”
Get full text

Editorial: Regenerative biologics for musculoskeletal injuries by Ashim Gupta, Ashim Gupta, Ashim Gupta, Anish G. Potty, Nicola Maffulli, Nicola Maffulli, Nicola Maffulli

Get full text

Bioprinting Au Natural: The Biologics of Bioinks by Kelsey Willson, Anthony Atala, James J. Yoo

“…To that end, we provide a broad overview of some of the biological molecules currently used as bioinks. Each molecule has advantages for specific tissues/cells, and potential disadvantages are discussed, along with examples of their current use in the field. …”
Get full text

Adverse reactions to biologics for psoriasis and countermeasures by Yang YANG, Dongmei SHI

Subjects: Get full text

Similar Biologics: Global Opportunities and Issues by Prasanta Kumar Ghosh

“…The regulatory authorities of different countries have authorized use of “similar biologics” based on comparative evaluation of each of such medicines with the inventor’s biologics; these are approved when considered to be closely similar to the inventor’s biologics in properties, quality and efficacy. …”
Get full text

Alpha-Gal-containing biologics and anaphylaxis by Yuko Chinuki, Eishin Morita

“…Cetuximab, the IgG1 subclass chimeric mouse-human monoclonal antibody biologic that targets the epidermal growth factor receptor (EGFR), is used worldwide for the treatment of EGFR-positive unresectable progressive/recurrent colorectal cancer and head and neck cancer. …”
Get full text

Oral Delivery of Biologics via the Intestine by Roger New

Subjects: Get full text